Sign Up Today and Learn More About OpenEvidence Stock
Invest in or calculate the value of your shares in OpenEvidence or other pre-IPO companies through EquityZen, part of Morgan Stanley.
OpenEvidence Stock (OPEV)
OpenEvidence is a common problem in many high-value domains. It's a huge challenge in medicine.
About OpenEvidence Stock
Founded
2021
Headquarters
Cambridge, MA, US
Total Funding
476M
Industries
Software, Data and Analytics, Science and Engineering
OpenEvidence provides a proprietary AI platform for life sciences companies. Founded by individuals from Harvard and MIT, the company's service synthesizes data from scientific sources, including medical literature and clinical trials, to support functions like R&D and medical affairs. The stated mission of the company is to accelerate the translation of scientific discovery into medical practice.
OpenEvidence Press Mentions
Stay in the know about the latest news on OpenEvidence
Medical AI Startup OpenEvidence Weighs $200 Million Funding Round
pymnts • Jul 20, 2026
Physicians Choose OpenEvidence Over Every Other AI Chatbot Combined in Independent Stanford-Harvard Study of Clinical AI
prnewswire • Jul 20, 2026
医疗AI独角兽OpenEvidence再传融资意向，潜在估值升至200亿美元
36kr • Jul 18, 2026
OpenEvidence adds real-time evidence quality grading to AI
techtarget • Jul 11, 2026
OpenEvidence Launches EvidenceGrade™, Empowering Physicians To See the Strength of Cited Evidence Beneath Each AI Answer
prnewswire • Jul 10, 2026
Join now and verify your accreditation status to gain access to:
- OpenEvidence Current Valuation
- OpenEvidence Stock Price
- OpenEvidence Management
- Available deals in OpenEvidence and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- OpenEvidence Cap Table and Funding History by Share Class and Liquidity Preferences
- OpenEvidence Revenue and Financials
- OpenEvidence Highlights
- OpenEvidence Business Model
- OpenEvidence Risk Factors
- OpenEvidence Research Report from SACRA Research
Trading OpenEvidence Stock
How to invest in OpenEvidence stock?
Accredited investors can buy pre-IPO stock in companies like OpenEvidence through EquityZen funds. These investments are made available by existing OpenEvidence shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process for buying Pre-IPO Shares.
How to sell OpenEvidence stock?
Shareholders can sell their OpenEvidence stock through EquityZen's private company marketplace. EquityZen's network includes over 470K accredited investors interested in buying private company stock. Learn more about the Shareholder liquidity process.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. See more information on Express Deals and pre-IPO exit information.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 55K private placements completed across 500+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
